Misato Ota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Misato Ota has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Toshiaki Makino
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, 467-8603, Japan
7 shared publications - Yasuhito Maki
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan; Kuki Sangyo Co., Ltd., 11 Onoe-cho, Yokkaichi-shi, Mie, 510-0059, Japan
3 shared publications Ichiro Utaka
Kuki Sangyo Co., Ltd. Yokkaichi Japan
2 shared publications- Ling-Yu Xu
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan
2 shared publications Sachie Arima
East‐Asian Traditional Medicine Center, Nagoya City University Hospital Nagoya Japan
2 shared publicationsShunsuke Nojiri
East‐Asian Traditional Medicine Center, Nagoya City University Hospital Nagoya Japan
2 shared publications
Latest Publications
- Open Access
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1726521
Historical studies on the use of Rhubarb in Japan
Background: Rhubarb product is the crude drug derived from the root or rhizome of Rheum or other related plants, and has been used since ancient times in Asian and European countries. However, the original plant species for Rhubarb product had been confused throughout its long history and across different areas. Methods: The present study aimed to identify the original plant species for Rhubab products used in Japan through histological analysis of medicinal literature, successive Japanese Pharmacopoeias, and the textbooks of crude drugs published from the mid-Edo period (1603–1868) to the early Showa era (1926–1989). Results: During the Edo period, Rumex madaio (synonym, Rumex daiwoo ), a plant that grows wild in Japan, was initially recognized as the origin of Rhubarb product. However, our present study indicates that, after Rheum rhabarbarum was imported from continental China in the 16th century, it was cultivated as the origin of true Rhubarb product. Since Rhubarb product derived from Rheum rhabarbarum has weak laxative effects, it is reasonable to infer that strong laxative effects were not anticipated in Japan at that time. Meanwhile, Rhubarb product derived from Rheum palmatum was known in Japan as Russian Rhubarb. Rheum palmatum had spread from continental China to Europe via Russia, and had been introduced to Japan as a laxative when Dutch medicine was introduced in the late-Edo period. Since the Meiji era (1868–1912) in Japan, the use of Rhubarb product during the Edo period had been re-evaluated, and Rhubarb product in Japan had been registered in the Japanese Pharmacopoeia. However, the publications in the Meiji era were reluctant to recognize that the Rhubarb product known as Toh -Rhubarb used by Japanese traditional Kampo physicians had derived from Rheum rhabarbarum . As a result, the two Rhubarb products were distributed separately, apart from those derived from Rheum palmatum . One was used by Kampo physicians and derived from Rheum plants grown in continental China, and referred to as Toh -Rhubarb. The other, derived from Rheum rhabarbarum, was referred to as Wa -Rhubarb. Conclusion: Consequently, the names and origins of Rhubarb products had been changed after the Meiji era from those used during the Edo period.
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1726521
Open AccessHistorical studies on the use of Rhubarb in Japan
Background: Rhubarb product is the crude drug derived from the root or rhizome of Rheum or other related plants, and has been used since ancient times in Asian and European countries. However, the original plant species for Rhubarb product had been confused throughout its long history and across different areas. Methods: The present study aimed to identify the original plant species for Rhubab products used in Japan through histological analysis of medicinal literature, successive Japanese Pharmacopoeias, and the textbooks of crude drugs published from the mid-Edo period (1603–1868) to the early Showa era (1926–1989). Results: During the Edo period, Rumex madaio (synonym, Rumex daiwoo ), a plant that grows wild in Japan, was initially recognized as the origin of Rhubarb product. However, our present study indicates that, after Rheum rhabarbarum was imported from continental China in the 16th century, it was cultivated as the origin of true Rhubarb product. Since Rhubarb product derived from Rheum rhabarbarum has weak laxative effects, it is reasonable to infer that strong laxative effects were not anticipated in Japan at that time. Meanwhile, Rhubarb product derived from Rheum palmatum was known in Japan as Russian Rhubarb. Rheum palmatum had spread from continental China to Europe via Russia, and had been introduced to Japan as a laxative when Dutch medicine was introduced in the late-Edo period. Since the Meiji era (1868–1912) in Japan, the use of Rhubarb product during the Edo period had been re-evaluated, and Rhubarb product in Japan had been registered in the Japanese Pharmacopoeia. However, the publications in the Meiji era were reluctant to recognize that the Rhubarb product known as Toh -Rhubarb used by Japanese traditional Kampo physicians had derived from Rheum rhabarbarum . As a result, the two Rhubarb products were distributed separately, apart from those derived from Rheum palmatum . One was used by Kampo physicians and derived from Rheum plants grown in continental China, and referred to as Toh -Rhubarb. The other, derived from Rheum rhabarbarum, was referred to as Wa -Rhubarb. Conclusion: Consequently, the names and origins of Rhubarb products had been changed after the Meiji era from those used during the Edo period.
- 2 October 2023
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 10 (3) , 269-277
Safety evaluation of continuous administration of a high dose of Valeriana fauriei root extract in mice and in humans through an open‐label study
Aim: This study aimed to clarify the safety of Valeriana fauriei root (VF) ethanol extract through in vivo and clinical trials.Methods: Mice were divided into VF and control groups. They were given VF (4 g VF/kg/day) or the vehicle mixed in the powdered food for four weeks. Food consumption and body weight changes were evaluated, and blood biochemistry and organ weights were assessed on the last day. In addition, an open‐label study was conducted on healthy subjects who took VF capsules (10 g VF/body/day) for four weeks and were asked to report any changes in their physical condition. Physical, hematologic, blood biochemical examination and urinalysis were performed before, two weeks, and four weeks into the study.Results: Food consumption and weight gain in mice did not differ between the VF and control groups, except for experimental error, and there were no particular differences in the weights of the brain, lung, heart, liver, spleen, and kidney. In mice, VF administration resulted in small but significant decreases in albumin in males and females, and total cholesterol and high‐density lipoprotein cholesterol in females only. These levels were unchanged, but daytime sleepiness was observed in humans.Conclusion: Since there was little change in the experimental values at continuous high doses of VF at 10 g/day, it can be concluded that approximately one‐fifth of this dose (2 g VF/day) is less harmful. However, daytime sleepiness should be considered.
- 2 October 2023
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 10 (3) , 269-277
Safety evaluation of continuous administration of a high dose of Valeriana fauriei root extract in mice and in humans through an open‐label study
Aim: This study aimed to clarify the safety of Valeriana fauriei root (VF) ethanol extract through in vivo and clinical trials.Methods: Mice were divided into VF and control groups. They were given VF (4 g VF/kg/day) or the vehicle mixed in the powdered food for four weeks. Food consumption and body weight changes were evaluated, and blood biochemistry and organ weights were assessed on the last day. In addition, an open‐label study was conducted on healthy subjects who took VF capsules (10 g VF/body/day) for four weeks and were asked to report any changes in their physical condition. Physical, hematologic, blood biochemical examination and urinalysis were performed before, two weeks, and four weeks into the study.Results: Food consumption and weight gain in mice did not differ between the VF and control groups, except for experimental error, and there were no particular differences in the weights of the brain, lung, heart, liver, spleen, and kidney. In mice, VF administration resulted in small but significant decreases in albumin in males and females, and total cholesterol and high‐density lipoprotein cholesterol in females only. These levels were unchanged, but daytime sleepiness was observed in humans.Conclusion: Since there was little change in the experimental values at continuous high doses of VF at 10 g/day, it can be concluded that approximately one‐fifth of this dose (2 g VF/day) is less harmful. However, daytime sleepiness should be considered.
- 12 July 2023
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 10 (2) , 177-184
Evaluation of capsules containing Valeriana fauriei root extract for sleep improvement: A randomized, double‐blind, placebo‐controlled, cross‐over comparative trial
Aim: This clinical trial aimed to clarify the sleep‐ameliorating effects of capsules containing Valeriana fauriei root (VF) extract and their adverse effects.Methods: The trial was a randomized, double‐blind, placebo‐controlled, cross‐over comparative clinical trial involving participants with an Athens Insomnia Scale (AIS) of 6 or higher, selected by prescreening questionnaires. After randomization, the participants took VF (2 g as VF/day) or placebo capsules for two weeks and were asked to complete the Obstructive Sleep Apnea (OSA) sleep questionnaire daily to assess their sleep status and any changes in their physical condition. On the last day of each term, the participants reported their sleep improvement experience.Results: No significant differences were found between the VF and placebo groups on the OSA sleep questionnaire. Significantly, more participants in the VF‐treated group experienced improvements in sleep onset and quality than those in the placebo group. The sleep onset improved particularly in those with early awakening, whereas the sleep quality particularly improved in those with midnight awakening. Although a few participants experienced physical, gastrointestinal and psychological changes when taking VF capsules, there was no significant difference from the placebo group, and no serious adverse events occurred.Conclusion: We clinically determined that VF, a folk medicine, improves sleep onset and sleep quality in people with suspected insomnia without serious adverse events at the dosage of 2 g VF/day.
- 12 July 2023
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 10 (2) , 177-184
Evaluation of capsules containing Valeriana fauriei root extract for sleep improvement: A randomized, double‐blind, placebo‐controlled, cross‐over comparative trial
Aim: This clinical trial aimed to clarify the sleep‐ameliorating effects of capsules containing Valeriana fauriei root (VF) extract and their adverse effects.Methods: The trial was a randomized, double‐blind, placebo‐controlled, cross‐over comparative clinical trial involving participants with an Athens Insomnia Scale (AIS) of 6 or higher, selected by prescreening questionnaires. After randomization, the participants took VF (2 g as VF/day) or placebo capsules for two weeks and were asked to complete the Obstructive Sleep Apnea (OSA) sleep questionnaire daily to assess their sleep status and any changes in their physical condition. On the last day of each term, the participants reported their sleep improvement experience.Results: No significant differences were found between the VF and placebo groups on the OSA sleep questionnaire. Significantly, more participants in the VF‐treated group experienced improvements in sleep onset and quality than those in the placebo group. The sleep onset improved particularly in those with early awakening, whereas the sleep quality particularly improved in those with midnight awakening. Although a few participants experienced physical, gastrointestinal and psychological changes when taking VF capsules, there was no significant difference from the placebo group, and no serious adverse events occurred.Conclusion: We clinically determined that VF, a folk medicine, improves sleep onset and sleep quality in people with suspected insomnia without serious adverse events at the dosage of 2 g VF/day.
- 12 August 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 298, 115625
Prolonging effects of Valeriana fauriei root extract on pentobarbital-induced sleep in caffeine-induced insomnia model mice and the pharmacokinetics of its active ingredients under conditions of glycerol fatty acid ester as emulsifiers
- 12 August 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 298, 115625
Prolonging effects of Valeriana fauriei root extract on pentobarbital-induced sleep in caffeine-induced insomnia model mice and the pharmacokinetics of its active ingredients under conditions of glycerol fatty acid ester as emulsifiers
- 18 February 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 292, 115108
History and the immunostimulatory effects of heat-processed licorice root products with or without honey
- 18 February 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 292, 115108
History and the immunostimulatory effects of heat-processed licorice root products with or without honey